Inhibitors for the Raf/MEK/ERK pathway include the MEK inhibitor trametinib194 and selumetinib, which resulted in shrinkage in neurofibromin-related gliomas in the optic pathway195, becoming the first FDA-approved treatment for inoperable plexiform neurofibroma196. The gene discussed is MAP2K7; the disease is glioma.